Sponsor

Rhythm Pharmaceuticals, Inc.

Clinical research sponsor

Published trials31
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

31 shown
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 · lead sponsor · 2025-09-23
RECRUITING
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentNCT06239116 · lead sponsor · 2024-03-05
RECRUITING
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)NCT07156578 · lead sponsor · 2025-11-10
ENROLLING_BY_INVITATION
A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 · lead sponsor · 2025-03-04
ACTIVE_NOT_RECRUITING
Open-Label Extension Study of SetmelanotideNCT06596135 · lead sponsor · 2024-10-21
COMPLETED
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityNCT06046443 · lead sponsor · 2024-07-11
COMPLETED
A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · lead sponsor · 2023-04-26
ACTIVE_NOT_RECRUITING
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741 · lead sponsor · 2022-03-08
COMPLETED
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNCT05194124 · lead sponsor · 2021-12-21
COMPLETED
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634 · lead sponsor · 2021-12-10
COMPLETED
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231 · lead sponsor · 2021-11-30
COMPLETED
Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240 · lead sponsor · 2021-06-07
COMPLETED
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR GenesNCT03621007 · lead sponsor · 2019-08-06
COMPLETED
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522 · lead sponsor · 2018-11-23
COMPLETED
Long Term Extension Trial of SetmelanotideNCT03651765 · lead sponsor · 2018-07-15
COMPLETED
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) RegistryNCT03479437 · lead sponsor · 2018-04-15
COMPLETED
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityNCT03287960 · lead sponsor · 2018-01-30
COMPLETED
Setmelanotide in a Single Patient With Partial LipodystrophyNCT03262610 · lead sponsor · 2017-08-15
COMPLETED
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192 · lead sponsor · 2017-02-14
COMPLETED
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543 · lead sponsor · 2017-02-10
COMPLETED
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult VolunteersNCT02849977 · lead sponsor · 2016-09-28
COMPLETED
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673 · lead sponsor · 2015-03-19
COMPLETED
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsNCT02041195 · lead sponsor · 2014-01-01
COMPLETED
Effects of RM-493 on Energy Expenditure in Obese IndividualsNCT01867437 · lead sponsor · 2013-05-01
COMPLETED
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137 · lead sponsor · 2013-01-14
COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic VolunteersNCT02431442 · lead sponsor · 2012-01-01
COMPLETED
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)NCT05183802 · lead sponsor
APPROVED_FOR_MARKETING
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityNCT07674290 · collaborator · 2023-01-01
RECRUITING
INDIcators for Clarifying the bAckground of exTreme Obesity in childRenNCT06420622 · collaborator · 2024-04-15
UNKNOWN
Early Genetic Identification of ObesityNCT06239064 · collaborator · 2024-01-24
ACTIVE_NOT_RECRUITING
Melanocortin 4 Receptor Mutations and Obesity-associated DiseasesNCT01849705 · collaborator · 2012-10-01
COMPLETED

Sponsor roles

lead sponsor27
collaborator4

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.